{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:18:59Z","timestamp":1790835539232,"version":"4.1.0"},"reference-count":35,"publisher":"Bioscientifica","issue":"1","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>For men with castration-resistant prostate cancer (CRPC), androgen-deprivation therapy (ADT) often becomes ineffective requiring the addition of docetaxel, a proven effective chemotherapy option. Tumor-associated macrophages (TAMs) are known to provide protumorigenic influences that contribute to treatment failure. In this study, we examined the contribution of TAMs to docetaxel treatment. An increased infiltration of macrophages in CRPC tumors was observed after treatment with docetaxel. Prostate cancer cells treated with docetaxel released more macrophage colony-stimulating factor (M-CSF-1 or CSF-1), IL-10 and other factors, which can recruit and modulate circulating monocytes to promote their protumorigenic functions. Inhibition of CSF-1 receptor kinase signaling with a small molecule antagonist (PLX3397) in CRPC models significantly reduces the infiltration of TAMs and their influences. As such, the addition of PLX3397 to docetaxel treatment resulted in a more durable tumor growth suppression than docetaxel alone. This study reveals a rational strategy to abrogate the influences of TAMs and extend the treatment response to docetaxel in CRPC.<\/jats:p>","DOI":"10.1530\/erc-18-0284","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T08:30:39Z","timestamp":1536654639000},"page":"131-140","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":36,"title":["Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer"],"prefix":"10.1530","volume":"26","author":[{"given":"Wei","family":"Guan","sequence":"first","affiliation":[{"name":"1Department of Urology and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Hu","sequence":"additional","affiliation":[{"name":"1Department of Urology and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"2Department of Paediatric Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"3Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[{"name":"4Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Tan","sequence":"additional","affiliation":[{"name":"4Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Tang","sequence":"additional","affiliation":[{"name":"4Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L","family":"West","sequence":"additional","affiliation":[{"name":"5Plexxikon Inc., Berkeley, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Bollag","sequence":"additional","affiliation":[{"name":"5Plexxikon Inc., Berkeley, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xu","sequence":"additional","affiliation":[{"name":"1Department of Urology and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Wu","sequence":"additional","affiliation":[{"name":"3Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA"},{"name":"6Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA"},{"name":"7Department of Pediatrics, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA"},{"name":"8Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA"},{"name":"9Molecular Biology Institute, University of California at Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"ref191","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2147\/TCRM.S3397","article-title":"Weekly docetaxel in the treatment of metastatic breast cancer","volume":"4","year":"2008","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"ref201","first-page":"5","article-title":"Docetaxel for the treatment of hormone - refractory prostate cancer in","author":"PetrylakDP","year":"2003","journal-title":"Reviews Urology"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2147\/TCRM.S3133","article-title":"Docetaxel in the treatment of squamous cell carcinoma of the head and neck","volume":"4","year":"2008","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood-2009-08-237412","article-title":"Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy","volume":"115","year":"2010","journal-title":"Blood"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","year":"2017","journal-title":"Nature"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"8386","DOI":"10.1158\/0008-5472.CAN-09-1504","article-title":"Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer","volume":"69","year":"2009","journal-title":"Cancer Research"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/neuonc\/nov245","article-title":"Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study","volume":"18","year":"2016","journal-title":"Neuro-Oncology"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1158\/0008-5472.CAN-14-3373","article-title":"Macrophage blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant ascites in late-stage epithelial ovarian cancer","volume":"75","year":"2015","journal-title":"Cancer Research"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood-2006-11-010389","article-title":"Suppression of T-cell functions by human granulocyte arginase","volume":"108","year":"2006","journal-title":"Blood"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/0008-5472.CAN-14-0992","article-title":"CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy","volume":"75","year":"2015","journal-title":"Cancer Research"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1158\/0008-5472.CAN-13-1816","article-title":"Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy","volume":"74","year":"2014","journal-title":"Cancer Research"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor","volume":"373","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","article-title":"Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy","volume":"1","year":"2011","journal-title":"Cancer Discovery"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11934-016-0584-4","article-title":"Novel insights into molecular indicators of response and resistance to modern androgen-axis therapies in prostate cancer","volume":"17","year":"2016","journal-title":"Current Urology Reports"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-17-0019","article-title":"Immunotherapy of prostate cancer: facts and hopes","volume":"23","year":"2017","journal-title":"Clin Cancer Research"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1158\/1078-0432.CCR-16-3122","article-title":"The promise of targeting macrophages in cancer therapy","volume":"23","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"ref181","first-page":"117","article-title":"Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer","volume":"5","year":"2011","journal-title":"Drug Design, Development and Therapy"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1159\/000365530","article-title":"Sequential treatment with taxanes and novel anti-androgenic compounds in castration-resistant prostate cancer","volume":"37","year":"2014","journal-title":"Oncology Research and Treatment"},{"key":"ref291","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","year":"2017","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"ref251","first-page":"312re310","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"7","year":"2015","journal-title":"Science Translational Medicine"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","year":"2015","journal-title":"Lancet Oncology"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1158\/0008-5472.CAN-04-0465","article-title":"Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses","volume":"64","year":"2004","journal-title":"Cancer Research"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.urology.2013.01.061","article-title":"Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial","volume":"81","year":"2013","journal-title":"Urology"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1158\/0008-5472.CAN-12-3981","article-title":"CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer","volume":"73","year":"2013","journal-title":"Cancer Research"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00345-014-1406-2","article-title":"Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?","volume":"33","year":"2015","journal-title":"World Journal of Urology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1078-0432.CCR-14-2666","article-title":"Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer","volume":"21","year":"2015","journal-title":"Clin Cancer Research"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1200\/JCO.1998.16.11.3674","article-title":"Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance","volume":"16","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3816\/CLC.2002.s.010","article-title":"Docetaxel in second - line treatment of non - small - cell lung cancer Supplement https org","author":"FossellaFV","year":"2002","journal-title":"Clinical Lung Cancer"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/26\/1\/ERC-18-0284.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/26\/1\/ERC-18-0284.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:55:01Z","timestamp":1784555701000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/26\/1\/131-140\/25325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":35,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/erc-18-0284","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}